Cargando…

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival

Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory multiple myeloma and consequently presenting limited therapeutic options. We analyzed 13 sPCL for their sensitivity to BH3 mimetics targeting either BCL2 (venetoclax) or B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Champion, Ophélie, Soler, Alana, Maïga, Sophie, Bellanger, Céline, Pellat-Deceunynck, Catherine, Talbot, Alexis, Touzeau, Cyrille, Amiot, Martine, Gomez-Bougie, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393035/ https://www.ncbi.nlm.nih.gov/pubmed/37534243 http://dx.doi.org/10.3389/fonc.2023.1196005

Ejemplares similares

Computational design of BclxL inhibitors that target transmembrane domain interactions
por: Duart, Gerard, et al.
Publicado: (2023)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells
por: Martin-Sanchez, Diego, et al.
Publicado: (2017)

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
por: Tessoulin, Benoît, et al.
Publicado: (2019)

New mouse model of acute adult T‐cell leukemia generated by transplantation of AKT, BCLxL, and HBZ‐transduced T cells
por: Kasugai, Yumiko, et al.
Publicado: (2016)

BFL1 modulates apoptosis at the membrane level through a bifunctional and multimodal mechanism showing key differences with BCLXL
por: Flores-Romero, Hector, et al.
Publicado: (2018)

Survival and Neurogenesis-Promoting Effects of the Co-Overexpression of BCLXL and BDNF Genes on Wharton’s Jelly-Derived Mesenchymal Stem Cells
por: Borkowska, Paulina, et al.
Publicado: (2022)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of BCL and BCLXL following glucocorticoid treatment
por: van der Zwet, Jordy C.G., et al.
Publicado: (2022)

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups
por: Gomez-Bougie, Patricia, et al.
Publicado: (2014)

Ubiquitination of SARS-CoV-2 ORF7a Prevents Cell Death Induced by Recruiting BclXL To Activate ER Stress
por: Liu, Zhixin, et al.
Publicado: (2022)

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
por: Maïga, S, et al.
Publicado: (2013)

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
por: Brosseau, C, et al.
Publicado: (2014)

The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca(2+) flux from the endoplasmic reticulum to mitochondria
por: Fouqué, A, et al.
Publicado: (2016)

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma
por: Hanf, Matthieu, et al.
Publicado: (2016)

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
por: Descamps, G, et al.
Publicado: (2012)

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)–Specific Degrader DT2216
por: Thummuri, Dinesh, et al.
Publicado: (2022)

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
por: Chiron, D, et al.
Publicado: (2013)

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
por: Tessoulin, Benoît, et al.
Publicado: (2018)

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
por: Kervoëlen, Charlotte, et al.
Publicado: (2015)

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53(abnormal) myeloma cells independently of the p53 pathway
por: Surget, Sylvanie, et al.
Publicado: (2014)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
por: Bodet, L, et al.
Publicado: (2010)

2216. Pneumonia in the ICU: Epidemiology and Outcomes
por: Blaha, Michael, et al.
Publicado: (2019)

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
por: Benaniba, Lina, et al.
Publicado: (2019)

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
por: Lodé, L, et al.
Publicado: (2013)

TLR9 Ligand Induces the Generation of CD20+ Plasmablasts and Plasma Cells from CD27+ Memory B-Cells
por: Geffroy-Luseau, Alexandrine, et al.
Publicado: (2011)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
por: Gillardin, Pierre-Samuel, et al.
Publicado: (2017)

Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
por: Khan, Sajid, et al.
Publicado: (2023)

Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes
por: Gomez-Bougie, Patricia, et al.
Publicado: (2013)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
por: Jullien, Maxime, et al.
Publicado: (2020)

The Origin of the Plasma-Cell Heterogeneity
por: Pellat-Deceunynck, Catherine, et al.
Publicado: (2015)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Clinicopathological Concordance in 2216 Cases of Skin Biopsy over One Year: An Indian Experience
por: Malik, Akanksha, et al.
Publicado: (2020)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mav9hvq9aqvqnvrnjmt340irki